In a report of Lieser et al. [244], the construction of an effective anticancer drug delivery system for targeted tumor therapy was facilitated when therapeutic proteins were conjugated to an EGFR (epidermal growth factor receptor) ligand through an incorporated ncAA. Here, EGFR is linked to neoplasm.